

Kiener Peter A
 Form 3/A
 September 09, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * ^ ^ Kiener Peter A (Last) (First) (Middle)		2. Date of Event Requiring Statement (Month/Day/Year) 05/19/2005	3. Issuer Name and Ticker or Trading Symbol MEDIMMUNE INC /DE [MEDI]	5. If Amendment, Date Original Filed(Month/Day/Year) 05/31/2005
C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY (Street)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director ____ 10% Owner <input checked="" type="checkbox"/> Officer ____ Other (give title below) (specify below) SVP, Research	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person ____ Form filed by More than One Reporting Person
GAITHERSBURG, MD 20878 (City) (State) (Zip)				

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Title Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	--	---	--	--	--

(Instr. 5)

Stock Option (Right to buy)	Â (1)	03/04/2014	Common Stock	30,000	\$ 23.45	D	Â
Stock Option (Right to buy)	Â (1)	02/15/2015	Common Stock	55,000	\$ 24.17	D	Â
Stock Option (Right to buy)	Â (1)	02/20/2013	Common Stock	30,000	\$ 29.34	D	Â
Stock Option (Right to buy)	Â (1)	09/01/2013	Common Stock	5,000	\$ 34.7	D	Â
Stock Option (Right to buy)	Â (1)	09/05/2011	Common Stock	30,000	\$ 40.85	D	Â
Stock Option (Right to buy)	Â (1)	02/21/2012	Common Stock	11,500	\$ 41.41	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kiener Peter A C/O MEDIMMUNE, INC. ONE MEDIMMUNE WAY GAITHERSBURG, MD 20878	Â	Â	Â SVP, Research	Â

Signatures

William C. Bertrand, Jr., as
attorney-in-fact

09/09/2005

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Grant exercisable in quarterly installments over a four year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.